RELAY THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.04 USD | -0.56% |
|
+10.52% | -36.06% |
| 05-02 | Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M | MT |
| 05-02 | Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,733 | 3,318 | 1,806 | 1,357 | 934.5 | - | - |
| Enterprise Value (EV) 1 | 3,309 | 3,061 | 1,712 | 1,267 | 758.1 | 798 | 879.1 |
| P/E ratio | -7.7 x | -8.04 x | -5.77 x | -3.95 x | -2.48 x | -2.49 x | -2.68 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 45.2 x | 1,095 x | 1,308 x | 53.1 x | 145 x | 115 x | 22.2 x |
| EV / Revenue | 40 x | 1,011 x | 1,240 x | 49.6 x | 118 x | 98.4 x | 20.9 x |
| EV / EBITDA | -63.3 x | -8.55 x | -5.8 x | -3.45 x | -1.94 x | -2.05 x | -2.01 x |
| EV / FCF | -31.7 x | -39.3 x | -7.18 x | -4.16 x | -3 x | -3 x | -3.44 x |
| FCF Yield | -3.16% | -2.54% | -13.9% | -24% | -33.4% | -33.3% | -29.1% |
| Price to Book | 4.9 x | 3.7 x | 1.76 x | 1.79 x | 1.3 x | - | - |
| Nbr of stocks (in thousands) | 89,811 | 108,044 | 120,895 | 123,269 | 132,742 | - | - |
| Reference price 2 | 41.56 | 30.71 | 14.94 | 11.01 | 7.040 | 7.040 | 7.040 |
| Announcement Date | 25/03/21 | 24/02/22 | 23/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 82.65 | 3.029 | 1.381 | 25.55 | 6.423 | 8.114 | 42.05 |
| EBITDA 1 | -52.25 | -357.9 | -295.1 | -367.7 | -390.4 | -390.1 | -437.9 |
| EBIT 1 | -55.8 | -361.9 | -299.3 | -373 | -399.3 | -408.1 | -407.2 |
| Operating Margin | -67.51% | -11,946.58% | -21,670.89% | -1,460.11% | -6,216.72% | -5,029.54% | -968.44% |
| Earnings before Tax (EBT) 1 | -52.41 | -363.9 | -290.5 | -342 | -375.3 | -390.7 | -396.6 |
| Net income 1 | -230.2 | -363.9 | -290.5 | -342 | -377.6 | -391.4 | -403.7 |
| Net margin | -278.51% | -12,012.94% | -21,036.13% | -1,338.66% | -5,879.41% | -4,823.79% | -960.21% |
| EPS 2 | -5.400 | -3.820 | -2.590 | -2.790 | -2.836 | -2.829 | -2.624 |
| Free Cash Flow 1 | -104.4 | -77.88 | -238.6 | -304.4 | -253 | -265.7 | -255.6 |
| FCF margin | -126.33% | -2,571.05% | -17,273.86% | -1,191.74% | -3,939.56% | -3,275.13% | -608.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 25/03/21 | 24/02/22 | 23/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.567 | 0.419 | 0.365 | 0.344 | 0.253 | 0.226 | 0.119 | 25.2 | - | 10.01 | 0.02 | 0.04 | 0.02 | - | - |
| EBITDA 1 | -65.85 | - | - | - | - | -99.98 | -104.7 | -72.21 | -90.82 | -88.97 | -98.27 | -95.75 | -93.16 | -98.09 | -100.5 |
| EBIT 1 | -66.89 | -62.72 | -77.81 | -85.89 | -72.85 | -101.2 | -106 | -73.58 | -92.2 | -90.36 | -102.5 | -101.7 | -101.1 | -101.9 | -104.3 |
| Operating Margin | -11,796.65% | -14,969.21% | -21,318.08% | -24,968.6% | -28,794.86% | -44,768.58% | -89,117.65% | -291.95% | - | -903% | -512,534% | -254,325% | -505,487% | - | - |
| Earnings before Tax (EBT) 1 | -67.46 | -62.05 | -76.79 | -84.17 | -67.5 | -94.24 | -98.5 | -65.73 | -83.5 | -81.39 | -95.9 | -95.5 | -95.16 | -98.38 | -100.3 |
| Net income 1 | -67.46 | -62.05 | -76.79 | -84.17 | -67.5 | -94.24 | -98.5 | -65.73 | -83.5 | -81.39 | -89.21 | -96.84 | -88.8 | -100.3 | -102.5 |
| Net margin | -11,897% | -14,808.11% | -21,037.81% | -24,468.6% | -26,681.03% | -41,698.67% | -82,777.31% | -260.83% | - | -813.3% | -446,048.35% | -242,087.5% | -444,024.15% | - | - |
| EPS 2 | -0.6200 | -0.5700 | -0.7100 | -0.7600 | -0.5600 | -0.7800 | -0.8100 | -0.5400 | -0.6700 | -0.6200 | -0.7347 | -0.7278 | -0.7242 | -0.7000 | -0.7133 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 08/08/23 | 02/11/23 | 22/02/24 | 02/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 423 | 257 | 94.1 | 90.3 | 176 | 137 | 55.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -104 | -77.9 | -239 | -304 | -253 | -266 | -256 |
| ROE (net income / shareholders' equity) | -79% | -43.8% | -31.4% | -40.2% | -59.4% | -51% | -45.9% |
| ROA (Net income/ Total Assets) | -38.6% | -40.2% | -27.6% | -35.2% | -42.3% | -40% | -35.9% |
| Assets 1 | 596.4 | 904.1 | 1,054 | 971.9 | 892.2 | 978.1 | 1,124 |
| Book Value Per Share 2 | 8.480 | 8.300 | 8.470 | 6.130 | 5.410 | - | - |
| Cash Flow per Share 2 | - | -0.7800 | -2.040 | -2.450 | -2.280 | -1.920 | - |
| Capex 1 | 1.93 | 3.47 | 9.06 | 4.13 | 7.12 | 5.06 | 5.1 |
| Capex / Sales | 2.34% | 114.59% | 656.19% | 16.15% | 110.85% | 62.42% | 12.12% |
| Announcement Date | 25/03/21 | 24/02/22 | 23/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
7.04
USD
Average target price
22.69
USD
Spread / Average Target
+222.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.06% | 935M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- RLAY Stock
- Financials Relay Therapeutics, Inc.
